Overview

Aciclovir Versus Placebo for HSV-2 Meningitis

Status:
Not yet recruiting

Trial end date:
2028-06-01

Target enrollment:

Participant gender:

Summary

To determine whether active treatment with (val)acyclovir is superior for treatment of viral meningitis compared with placebo assessed by numbers meeting a primary, objective endpoint at 7 days after randomisation

Phase:

Phase 4

Details

Lead Sponsor:

Jacob Bodilsen

Treatments:

Acyclovir
Valacyclovir